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ABSTRACT
Introduction: Basal insulin (BI) plays an
important role in treating type 2 diabetes (T2D),
especially when oral antidiabetic (OAD) medi-
cations are insufficient for glycemic control. We
conducted a retrospective, observational study
using electronic medical records (EMR) data
from the IBM Explorys database to evaluate
the probability of achieving glycemic control
over 24 months after BI initiation in patients
with T2D in the USA.
Methods: A cohort of 6597 patients with T2D
who started BI following OAD(s) and had at
least one valid glycated hemoglobin (HbA1c)
result recorded both within 90 days before and
720 days after BI initiation were selected. We
estimated the changes from baseline in HbA1c
every 6 months, the quarterly conditional
probabilities of reaching HbA1c\ 7% if a
patient had not achieved glycemic control prior
to each quarter (Q), and the cumulative proba-
bility of reaching glycemic control over
24 months.
Results: Our cohort was representative of
patients with T2D who initiated BI from OADs
in the USA. The average HbA1c was 9.1% at BI
initiation, and decreased robustly (1.5%) in the
first 6 months after initiation with no further
reductions thereafter. The conditional proba-
bility of reaching glycemic control decreased
rapidly in the first year (26.6% in Q2; 17.6% in
Q3; 8.6% in Q4), and then remained low
(B 6.1%) for each quarter in the second year.
Cumulatively, about 38% of patients reached
HbA1c\ 7% in the first year; only approxi-
mately 8% more did so in the second year.
Conclusion: Our study of real-world data from
a large US EMR database suggested that among
patients with T2D who initiated BI after OADs,
the likelihood of reaching glycemic control
diminished over time, and remained low from
12 months onwards. Additional treatment
options should be considered if patients do not
reach glycemic control within 12 months of BI
initiation.
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INTRODUCTION
Type 2 diabetes (T2D) affects 30.3 million peo-
ple (* 9.4% of the population) in the USA as of
2017 [1]. The economic and social costs of T2D
are considerable because of its associated serious
short- and long-term complications, particu-
larly in patients who do not achieve and/or
maintain glycemic control [2, 3], as well as its
significant contribution to overall mortality
(approximately 12% of all deaths) [4]. Hyper-
glycemia, which may result from insufficient
treatment intensification, significantly increa-
ses the risks of microvascular complications,
such as retinopathy and nephropathy, as well as
macrovascular complications including
myocardial infarction, heart failure, stroke, and
their composite [3, 5]. The American Diabetes
Association (ADA) Standards of Medical Care in
Diabetes recommend that most adult patients
with T2D maintain a glycated hemoglobin
(HbA1c) level at\ 7% [6].
Over the past three decades, there has been
considerable progress in the development of
new antihyperglycemic medications for
patients with T2D. Therapeutic options now
include novel agents such as dipeptidyl pepti-
dase 4 (DPP4) inhibitors, sodium–glucose
cotransporter 2 (SGLT-2) inhibitors, as well as
injectable glucagon-like peptide 1 receptor
agonists (GLP-1 RAs). While oral antidiabetics
(OADs) are usually the first- or second-line
options, many patients with T2D will eventu-
ally require therapy with injectables including
insulin therapy. Basal insulin (BI) has been
shown to be effective in reducing HbA1c levels
and attaining glycemic control, with between
40% and 70% of patients reaching a target of
\7% in randomized controlled trials (RCTs)
[7, 8]. Initiating insulin replacement with BI has
been endorsed in professional guidelines for
patients who have not attained target HbA1c
levels with the use of non-insulin therapies
[9, 10].
Studies of the effectiveness of BI in real-
world practice have shown mixed results. The
proportions of patients achieving target HbA1c
levels (HbA1c\7%) in these studies have ran-
ged from as low as 11% after 1 year to as high as
58% over 2.5 years [11–19]. The likelihood of
reaching glycemic control with BI treatment in
the real world remains a question of interest to
patients, clinicians, healthcare systems, and
payers.
The IBM Watson HealthTM Explorys data-
base (later referred to as Explorys) is a large, US
population-based, commercial database that
contains an aggregate of electronic medical
record (EMR) data from over 54 million unique
patients from 39 major integrated healthcare
systems covering over 344,000 clinicians across
all 50 US states. It contains de-identified,
structured, longitudinal patient data (including
diagnoses, laboratory results, biometric mea-
sures, and procedures) from clinical encounters
at participating institutions. Collected data are
standardized and normalized by IBM Watson
Health. The data are automatically updated at
least once every 24 h. This database offers a
good means of studying the real-world evidence
for the effectiveness of different treatment
modalities (including BI) in the USA.
We conducted a retrospective, observational
study using the Explorys database to evaluate
the probability of achieving glycemic control
over 24 months after BI initiation in patients
with T2D.
METHODS
Study Cohort Construction
Within the Explorys dataset (from 2000 to
November 3, 2017), we created a diabetes
cohort by selecting all patients with at least one
encounter with a diagnostic code (primary or
secondary) for T2D (ICD9 codes 250.x0, 250.x2,
and ICD10 code E11.*), an HbA1c mea-
sure C 6.5%, or a prescription for an antidia-
betic medication. We excluded those who had a
diagnosis of type 1 diabetes, gestational dia-
betes, or polycystic ovarian syndrome. This
resulted in a set of * 4.27 million patients,
among whom * 2.3 million had at least one
valid prescription for antidiabetic medication.
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Among the * 2.3 million patients, 69% had at
least one OAD prescription and 24% had at least
one prescription of BI [neutral protamine
Hagedorn (NPH), glargine, detemir, or deglu-
dec]. Approximately 85% of BI prescriptions
identified for this study were filled after 2011.
For this analysis, we were interested in
patients who progressed from any OAD regimen
to BI. To assess treatment regimens we calcu-
lated prescription length as the time between
the prescription start date and prescription end
date. Where a valid prescription end date was
given, that date was used as provided. An end
date was considered valid if it occurred:
• Between 2000 and the analysis date and
• After the prescription start date and
• A maximum of 12 months after the prescrip-
tion date.
For oral prescriptions without end dates, we
used a proxy of twice as many days as the
median population valid prescription duration
past the start date. A valid prescription is a
prescription with a start date which is not the
same as the end date (if it exists), and where the
prescription is not flagged as erroneous or can-
celled. For insulin prescriptions without valid
end dates, we inferred the end date to be 1 year
after the prescription start date.
Our analysis cohort included patients who
had progressed to BI from one or more OAD(s).
Patients who did not have any encounters
recorded within Explorys for the year prior to
the first diabetes prescription were excluded.
The date of first prescription of BI was defined as
the index date. Patients were included if they
had at least one valid HbA1c test recorded (i.e.,
positive HbA1c value) within 90 days prior to
and including the index date AND at least one
valid HbA1c test recorded within 24 months
(720 days) after the index date. If a patient had
multiple valid HbA1c records prior to (and
including) the index date, the last value was
used as the baseline. Patient follow-up contin-
ued until the first BI regimen ended or was
changed, until they reached 2 years after BI
initiation, or until the database cutoff date for
this analysis was reached. Overlapping BI pre-
scriptions or BI prescriptions with\ 90 days of
gap between the end of one prescription and
the start of another were collapsed into the
same regimen. Only outpatient BI prescriptions
were included in the analysis. Data were strati-
fied by the number of concomitant OADs at the
time of BI initiation (i.e., BI only, BI ? 1 OAD,
BI ? 2 OADs, and BI ? C 3 OADs), creating four
subcohorts. A flow diagram showing inclusion
and exclusion of the patients in the study
cohort is shown in Fig. 1.
This article is based on the existing EMR
database and does not contain any studies with
human participants or animals performed by
any of the authors.
Statistical Approach
Descriptive statistics were calculated to describe
the baseline demographics and clinical charac-
teristics of the study cohort and subcohorts.
Means and standard deviations (SD) are repor-
ted for continuous variables and percentages are
provided for categorical variables.
Each quarter post-index date was defined to
be 90 days, i.e., 0–90 days as the first quarter
(0–3 months); 91–180 days as the second quar-
ter (3–6 months), etc. The descriptive statistics
of HbA1c change from baseline were calculated
semi-annually (i.e., every 180 days) following BI
initiation.
To assess the patients’ response to BI treat-
ment within 24 months after the index date, we
defined the target goal of glycemic control as
achieving an HbA1c\7%. We calculated the
percentage of patients who reached glycemic
control for the first time among those who had
not reached glycemic control and were still on
BI and had any EMR record in the correspond-
ing periods.
We estimated the probability of achieving
glycemic control after BI initiation in two ways:
1. The conditional probability was estimated
as the proportion of patients who reached
their first glycemic control within a specific
quarter among those patients who had not
previously achieved glycemic control, who
were still taking their BI regimen, and who
had a valid HbA1c test recorded in that
quarter. As this denominator changed at
each quarter, conditional probability was
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calculated quarterly, not cumulatively over
time.
2. The cumulative probability of patients
reaching first glycemic control over time
was estimated via Kaplan–Meier curves for
the whole study cohort as well as the four
subcohorts. Log-rank tests were done to
compare the subcohorts. Censoring
occurred at the end of the BI regimen
(including switching to a new non-BI regi-
men), loss of record in the database, or the
cutoff date for the analysis.
RESULTS
Baseline Demographics and Clinical
Characteristics
Our study cohort included a total of 6597
patients selected from the clinical EMR database
(Fig. 1). Patient demographic and clinical char-
acteristics data at baseline (i.e., last value within
90 days prior to and including the index date)
are shown in Table 1. The study cohort was
representative of the US population with T2D in
terms of age (62 ± 12.7 years), race (75% white,
13% African-American), insurance coverage
(47% private, 36% Medicare, 7% Medicaid) and
most common comorbidities (81% hyperten-
sion, 70% obesity, 50% dyslipidemia, 24% heart
disease, and 20% anemia, which may be asso-
ciated with diabetic chronic kidney disease).
The most common OADs taken were metformin
(79%), sulfonylureas (63%), DPP4 inhibitors
(30%), and thiazolidinediones (24%). At BI ini-
tiation, the mean (SD) of HbA1c was 9.1%
(2.1%), with 3219 (48.8%) of the 6597 patients
having an HbA1c[9%. Before BI initiation,
3856 (58.5%) of the 6597 patients were on one
OAD only, 2032 (30.8%) were on two OADs,
and 709 (10.7%) were on at least three OADs. At
BI initiation, about 20% of patients were pre-
scribed BI alone, while 40%, 31%, and 9% were
prescribed BI together with one OAD, two
OADs, and at least three OADs, respectively
(Table 2). The four subcohorts appeared to be
similar in terms of age, sex, HbA1c, and body
mass index at baseline. Diabetes duration could
not be provided, as the diagnosis of T2D for
some patients predated their entry into the
Explorys database.
Fig. 1 Patient selection from the database. BI basal insulin, HbA1c glycated hemoglobin, OAD oral antidiabetic, T2D type
2 diabetes
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HbA1c Change Over Time
Based on the available HbA1c data in the cohort
in each 6-month interval, the change from
baseline in HbA1c was estimated. Mean (SD)
HbA1c decreased 1.49 (2.63) percentage points
from baseline to 6 months, with no further
reductions thereafter (Table 3). As not all
patients had an HbA1c value in each period, the
members of the cohort differed in each period.
Patients Achieving Glycemic Control
(HbA1c < 7%)
The percentage of patients who registered an
HbA1c\ 7% for the first time, out of the num-
ber of those patients who were still in the
cohort, was calculated for each quarter after the
index date (Fig. 2, Table 4). During the second
quarter after the index date, there were 6086
patients who had HbA1c C 7% prior to the
beginning of the period and were continuing on
Table 1 Baseline demographics and characteristics of the
study cohort and overall T2D cohorts in the Explorys
database
T2D patients in
the US IBM
Explorys database
as of November 3,
2017
(N = 4.27 M)
Study cohort at
time of BI
initiation
(n = 6597)
Female, n (%) 2.27 M (53) 3042 (46)
Mean
age ± SD,
years
58 ± 15.7 62 ± 12.7
Median age,
years
60 62
C65 years,
n (%)
1.65 M (38.7) 3042 (43)
Race, n (%)
White 2.6 M (61) 4979 (75)
African-
American
574 K (14) 882 (13)
Asian 85 K (2) 67 (1)
Ethnicity, n (%)
Hispanic/
Latino
243 K (6) 466 (7)
Unknown 1.1 M (27) 318 (5)
Insurance, n (%)
Private 1.6 M (38) 3099 (47)
Medicare 1.1 M (27) 2377 (36)
Self-pay 185 K (5) 192 (3)
Medicaid 241 K (6) 425 (7)
Unknown 1 M (23) 205 (3)
Comorbidity, n (%)
Hypertension 2.6 M (62) 5336 (81)
Dyslipidemia 1.3 M (30) 3308 (50)
Obesity 2.1 M (50) 4671 (70)
Anemia 1 M (24) 1352 (20)
Heart disease 1 M (23) 1584 (24)
Table 1 continued
T2D patients in
the US IBM
Explorys database
as of November 3,
2017
(N = 4.27 M)
Study cohort at
time of BI
initiation
(n = 6597)
Prescription medication, n (%)
OADs N/A 6597 (100)
Metformin N/A 5206 (79)
Sulfonylureas N/A 4135 (63)
DPP4
inhibitors
N/A 2006 (30)
TZDs N/A 1561 (24)
SGLT-2
inhibitors
N/A 206 (3)
BI N/A 6597 (100)
BI basal insulin, DPP4 dipeptidyl peptidase 4, K thousand,
M million, OAD oral antidiabetic, SD standard deviation,
SGLT-2 sodium–glucose cotransporter 2, T2D type 2
diabetes, TZD thiazolidinedione
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BI treatment, among whom a total of 1311
(21.5%) patients had reached HbA1c\ 7% for
the first time in that quarter. Similar calcula-
tions were done for every subsequent quarter
until 24 months. The percentages of patients
reaching HbA1c\7% for the first time in that
quarter are shown in Fig. 2 and Table 4, column
E.
Estimation of Conditional Probabilities
In each quarter post-index date, approximately
2/3 of the patients had a valid HbA1c mea-
surement (Table 4, columns B and C). From
patients who had a valid HbA1c measurement,
we estimated the conditional probabilities of
reaching the glycemic target of HbA1c\ 7% for
the first time beginning at the second quarter
after BI initiation (Table 4, column F). For those
patients who had not reached HbA1c\7% in
the first quarter (90 days) following BI initia-
tion, the probability of reaching first glycemic
control in the second quarter was 26.6%. This
conditional probability decreased to 17.6%
during the third quarter and to 8.6% in the
fourth quarter after BI initiation. After
12 months post-BI initiation, it diminished
further to B 6.1% during any quarter in the
second year.
Table 2 Baseline characteristics of subcohorts at time of BI initiation
BI only BI 1 1
OAD
BI 1 2
OADs
BI 1 ‡3
OADs
Total
Patients, n (%) 1319 (20) 2658 (40) 2024 (31) 596 (9) 6597 (100)
Female, % 50 48 44 38 46
Mean ± SD age, years 64.5 ± 12.5 61.6 ± 13.1 60.8 ± 12.4 61.3 ± 11.5 61.9 ± 12.7
Mean ± SD HbA1c at BI initiation, % 8.7 ± 2.0 9.3 ± 2.2 9.3 ± 2.0 9.1 ± 2.0 9.1a ± 2.1
Mean ± SD BMI at BI initiation, kg/m2 33.2 ± 7.8 33.5 ± 7.6 33.8 ± 7.6 33.8 ± 7.3 33.6 ± 7.6
BI basal insulin, BMI body mass index, HbA1c glycated hemoglobin, OAD oral antidiabetic, SD standard deviation
a At baseline, 3219 (48.8%) of the 6597 patients had an HbA1c[ 9.0%
Table 3 HbA1c change over time in the ﬁrst 2 years post-
BI initiation
Duration
post-BI
initiation
Number of patients
with HbA1c records
in this period
HbA1c change
from baseline,
mean (SD)
0–6 months 5679 - 1.49 (2.63)
6–12 months 3600 - 1.43 (2.69)
12–18 months 861 - 1.44 (2.69)
18–24 months 331 - 1.49 (2.88)
Only those with a valid HbA1c record at baseline and the
corresponding time period were included for the calcula-
tions. Few patients had multiple HbA1c records across two
or more periods post-BI initiation
BI basal insulin, HbA1c glycated hemoglobin, SD standard
deviation
Fig. 2 Percentage of patients reaching their ﬁrst
HbA1c\ 7% post-BI initiation. The numerator is deﬁned
as the number of patients who reached glycemic control
(HbA1c\ 7%) for the ﬁrst time during each correspond-
ing quarter; the denominator is deﬁned as the number of
patients who did not reach glycemic control prior to that
quarter AND were still on BI treatment AND had at least
one valid electronic medical records entry in that quarter.
BI basal insulin, HbA1c glycated hemoglobin
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Time to Reach First Glycemic Control
Analyses
The Kaplan–Meier curves of the time to reach
HbA1c\7%showed similar trends for theoverall
cohort (Fig. 3, dotted line) aswell as across all four
subcohorts of concomitant OAD usage (Fig. 3,
solid lines). All curves rose gradually over the first
3 months, with a sharper increase over the
remainder of the first year, followed by a much
more gradual increase over the second year.
Overall, approximately 25%, 38%, 42%, and 46%
ofeligiblepatients achieved theirfirstHbA1c\7%
by 6, 12, 18, and 24 months after BI initiation,
respectively (estimated from the overall cohort
Kaplan–Meier curve). Patients in the two sub-
cohorts treated with BI only or BI ? 1 OAD
appeared to have a slightly higher rate of
achieving HbA1c\7% than those treated with
BI ? 2 or at least 3 OADs, but the differences
did not reach statistical significance (p = 0.27).
DISCUSSION
In this real-world study based on a large US EMR
database, our study cohort of patients initiating
BI from OAD(s) had a mean HbA1c of 9.1%, and
approximately 49% had an HbA1c[9.0% at
baseline. This underscores that patients may
remain on OAD(s) for extended periods, despite
being significantly above recommended gly-
cemic control targets. Further, it indicates that
the patients selected for RCTs of BI are generally
in better glycemic control than patients who
initiate BI in real life; in fact, the average base-
line HbA1c was higher in our study than in 36
of 44 RCTs of BI included in a systematic review
Table 4 Conditional probability of reaching ﬁrst glycemic control (HbA1c\ 7%)
A: time after
BI initiation
B: number of
patients who had not
reached glycemic
control previously
AND were still on
BI treatment within
this quarter
C: number of
patients who had not
reached glycemic
control previously
AND were still on
BI treatment AND
had at least one valid
HbA1c record
within this quarter
D: number of
patients who
reached their
ﬁrst glycemic
control within
this quarter
E: percentage
(%) of
patients in
column D
among the
patients in
column B
F: estimated
conditional
probability (% of
patients in column
D among patients
in column C), %
(95% CI)
3–6 months 6086 4933 1311 21.5 26.6 (25.4, 27.8)
6–9 months 4102 2767 487 11.9 17.6 (16.2, 19.0)
9–12 months 2423 1668 143 5.9 8.6 (7.3, 9.9)
12–15 months 1679 684 37 2.2 5.4 (3.7, 7.1)
15–18 months 597 361 22 3.7 6.1 (3.6, 8.6)
18–21 months 365 260 14 3.8 5.4 (2.7, 8.1)
21–24 months 216 147 5 2.3 3.4 (0.5, 6.3)
BI basal insulin, CI conﬁdence interval, HbA1c glycated hemoglobin
Fig. 3 Kaplan–Meier curves for time to reach glycemic
control (HbA1c\ 7%) for the overall study cohort and
the four subcohorts. BI basal insulin, HbA1c glycated
hemoglobin, OAD oral antidiabetic
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[7]. However, the results presented here are in
line with previous real-world studies in which
HbA1c at initiation of BI was well above the
recommended target, showing that early
intensification to the recommended BI treat-
ment is uncommon in routine clinical care
[11, 17, 18]. Factors underlying such delays are
complex [20–22] and may reflect physicians’
perceptions of patients’ lifestyles and non-ad-
herence to existing medications; and patients’
concerns about out-of-pocket expenses, and
reluctance to consider BI, as well as fear of
hypoglycemia and concern about weight gain
[11, 23].
After initiation of BI (with or without con-
comitant OADs), there was a robust drop in
mean HbA1c of about 1.5% over the first
6 months, but with no additional change from
baseline over subsequent quarters. Few real-
world studies have examined both HbA1c
change after 3–6 months of BI treatment and
after long-term follow-up [11, 12, 17]. A US
retrospective analysis of patients with T2D
found that in 4387 new initiators of BI with an
average HbA1c of 9.5% at baseline, the HbA1c
decrease of 1.3% at 3 months was the same as
the decrease from baseline at 12 months [11].
Similarly, a retrospective longitudinal analysis
of EMR from five European countries and the
USA showed a similar trend, with the majority
of the mean HbA1c decline within the initial
6 months, and no further improvement after
12 months [17]. As these data represent a cross-
sectional analysis of a cohort, no consideration
is given to the impact of patients who may
achieve control initially, and subsequently
return to an HbA1c C 7% again.
To better mimic the situation of the health-
care practitioner (HCP), we estimated the con-
ditional probability of reaching glycemic
control if continuing BI treatment, beginning in
the second quarter post-BI initiation until
2 years, given the condition that glycemic con-
trol has not been achieved up to the beginning
of the specific quarter. This provides a poten-
tially useful perspective for prescribers who
initiate their patients on BI and need to esti-
mate the likelihood over time that a patient will
achieve glycemic goals. Our study results sug-
gest that if a patient has been using the same BI
regimen for 6 or 12 months and has not yet
reached their glycemic target, the likelihood of
achieving success on the same regimen is low,
which should prompt consideration of treat-
ment modification or intensification. While the
estimated probabilities can be affected by the
relative robustness of the EMR database and
need further confirmation, the overall decreas-
ing trend and the very low probabilities of
reaching HbA1c targets after the first year
highlight the need for paying attention to
patients who have failed to achieve glycemic
targets in the first year following BI initiation.
There is often a delay in treatment intensifica-
tion despite persistently elevated glucose levels
[13, 14, 24]. In a real-world observational study
published in 2016, the median time to treat-
ment intensification in patients with elevated
HbA1c following BI initiation was 4.3 years [24].
Multiple factors may contribute to such delays
[25] including concerns related to some treat-
ment options beyond BI. Basal-bolus and pre-
mix insulin regimens are potential options, but
hypoglycemia, weight gain, and the need to
take multiple daily injections can be major
concerns [26–28]. With the recent development
of medications such as GLP-1 RAs, fixed-ratio
combinations of BIs and GLP-1 RAs, and SGLT2
inhibitors, which do not increase the risk of
hypoglycemia or induce weight gain [29–31],
prescribers now have more options to consider.
The cumulative probability of reaching gly-
cemic control over time (Fig. 3) revealed that
about 38% of patients reached glycemic control
in the first 12 months but only about 8% more
did so in the second year. These results are also
in line with other real-world research
[11, 17, 18] which has generally found little
further increase in rates of patients with HbA1c
below the glycemic target with extended treat-
ment. The previously mentioned US-based ret-
rospective analysis [11] found an increase in
patients below target for new initiators of BI,
from 11% at baseline to 27% at 3 months after
BI initiation; however, this fell to 25% after
12 months. The aforementioned retrospective
longitudinal EMR analysis from five European
countries and the USA [17] found that 20.9%
had an HbA1c B 7% at 3 months after BI initi-
ation; by 24 months post-initiation this had
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only increased to 27.8%. An additional US EMR
analysis found that 44% of its cohort achieved
HbA1c B 7% within 1 year after BI initiation,
with 58% reaching this goal over the entire 2.5-
year follow-up [18]. Differences in the patient
group (39.2% of this cohort had HbA1c[9% at
baseline, compared with 48.8% in our study)
and the specific glycemic goal may play a role in
the results.
In the current study, the subcohorts of
patients taking no or one concomitant OAD at
BI initiation had a slightly higher rate of
achieving HbA1c\7% than those taking two
or more OADs, which might reflect differences
in stage of disease progression. While the
Explorys database cannot definitively provide
disease duration for the majority of patients, it
is possible that those patients who continued
treatment with two or more OADs while initi-
ating BI were considered more progressed and
therefore had lower residual beta cell function,
which could impact glycemic response to BI
treatment. Corresponding broadly to results
seen here, a retrospective database analysis of
1830 patients found greater achievement of
glycemic targets among those patients taking
fewer OADs at baseline (38.2%, 26.7%, and
19.6% for patients taking one, two, and at least
three OADs, respectively; p\ 0.0001) [15].
There could have been other contributing fac-
tors; for example, patients on more medications
may have more challenges to be compliant with
the prescriptions.
Our study has some important limitations.
In the USA, patients change insurance coverage
and/or HCPs from time to time because of
employer decisions, job changes, relocations,
personal choices, etc.; the Health Insurance
Portability and Accountability Act rules typi-
cally preclude the database from linking multi-
ple records from different sources using
personal information. The EMR data collected
in the Explorys database provides only a snap-
shot of patients’ medical histories, and cannot
provide the rigor and completeness of data that
is typically expected from a prospective longi-
tudinal clinical trial. Laboratory variables are
assessed for clinical practice instead of research
purposes, and are from multiple sources,
obtained as per local clinical practices. HbA1c
measurements were not consistently performed
every 3 months in many patients, reducing the
assessable number of patients included in the
analysis. In addition, it is possible that HbA1c
measurements may have occurred outside of
the data capture infrastructure, and it cannot be
guaranteed that those patients with missing
HbA1c records behave the same as those with
available HbA1c results. The paucity of fasting
plasma glucose data and of dosing information
in the database are other limitations which
make it difficult to evaluate titration practice
after BI initiation, or any possible relationship
between insulin dose and glycemic response.
Given the difficulty of achieving glycemic goals
reported in real-world literature, clinicians may
find value in understanding which factors pre-
dict achievement of an HbA1c target. For
example, assessing durability of glycemic con-
trol in those treated with BI, along with treat-
ment patterns after BI initiation, can add
important further information on factors asso-
ciated with significantly higher rates of reach-
ing the goal of HbA1c B 7% [18]. We did not do
this analysis in our current study because of
limitations of the data, but it is our plan to do so
in ongoing studies.
CONCLUSIONS
Our study of real-world data from a large US
database suggests that, among patients with
T2D who initiated BI after the use of OADs, the
likelihood of newly reaching glycemic control
diminished over time, regardless of whether BI
was taken alone or together with OADs. The
ADA or American Association of Clinical
Endocrinologists guidelines recommend some
change to treatment if patients do not achieve
control within 3 months. Our data suggest that
maintaining a BI regimen over 12 or 24 months
in a patient who has not yet reached the
HbA1c\ 7% target provides little additional
benefit towards reaching this goal, and that
prescribers should consider additional medica-
tion options if a patient does not reach glycemic
control within 12 months of BI initiation.
Information generated from a large real-world
EMR database offers complementary
Diabetes Ther
information to that provided by RCTs, with the
potential for additional insights of use for HCPs,
healthcare systems, payers, and industry.
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